Table 3 Univariate analysis of clinicopathological prognostic factors (n = 178)

disease-free survival (DFS)

Age (>/< median)

0.912

0.509-1.633

n.s.

FIGO stage (III/IV vs. II vs. I)

2.112

1.486-3.002

< 0.001

Nodal involvement (N1 vs. N0)

3.125

1.750-5.579

< 0.001

Grading (G3 vs. G1/G2)

1.164

0.656-2.066

n.s.

histological type (adenomatous/adenosquamous vs. squamous)

1.118

0.597-2.093

n.s.

lymphatic invasion (L1 vs. L0)

2.934

1.300-6.621

0.010

depth of invasion (> 10 mm vs. 1-10 mm)

3.303

1.448-7.531

0.004

Adjuvant therapy (radiation vs. none)

1.834

0.961-3.499

0.066

Adjuvant therapy (chemoradiation vs.nNone)

0.743

0.325-1.699

n.s.

ALCAM IHC (positive vs. negative)

0.912

0.509-1.633

n.s.

cancer-specific survival (CSS)

Age (>/< median)

1.011

0.472-1.638

n.s.

FIGO stage (III/IV vs. II vs. I)

2.265

1.555-3.299

< 0.001

Nodal involvement (N1 vs. N0)

3.664

1.972-6.811

< 0.001

Grading (G3 vs. G1/G2)

1.325

0.715-2.457

n.s.

histological type (adenomatous/adenosquamous vs. squamous)

1.012

0.507-2.020

n.s.

lymphatic invasion (L1 vs. L0)

2.960

1.232-7.113

0.015

depth of invasion (> 10 mm vs. 1-10 mm)

3.221

1.325-7.831

0.010

Adjuvant therapy (radiation vs. none)

1.840

0.930-3.643

0.080

Adjuvant therapy (chemoradiation vs. none)

0.674

0.266-1.713

n.s.

ALCAM IHC (positive vs. negative)

0.880

0.472-1.638

n.s.